Regeneron Strikes $256M Deal for 23andMe; Customer Privacy Assured
Regeneron Pharmaceuticals will buy 23andMe’s assets for $256 million and work with a court-appointed privacy ombudsman to ensure customer data is protected, the pharmaceutical company announced Monday (see 2505060062).
Sign up for a free preview to unlock the rest of this article
Regeneron will comply with 23andMe’s “consumer privacy policies and applicable laws with respect to the treatment of customer data,” the company said: It’s ready to share the “intended use of customer data and the privacy programs and security controls in place for review by a court-appointed, independent Customer Privacy Ombudsman and other interested parties.”
Co-founder George Yancopoulos said Regeneron believes it can continue delivering 23andMe’s mission of helping consumers learn about DNA and how to improve their health, while also furthering its internal efforts on “large-scale genetics research.” The company said it will “prioritize the privacy, security and ethical use of 23andMe’s customer data.” The deal is subject to court and regulatory approvals.